Quick Answer
Arcadia Biosciences, Inc. reported Operating Income Loss of -$2.50 million for the year ending 2025.
- Arcadia Biosciences, Inc. showed an increase of +31.5% in Operating Income Loss from 2024 to 2025.
- This data is from Arcadia Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Arcadia Biosciences, Inc.'s Operating Income Loss has grown by 83.5%.
- Historical annual values: Fiscal year 2025: -$2.50 million | Fiscal year 2024: -$3.65 million | Fiscal year 2023: -$6.10 million | Fiscal year 2022: -$14.01 million | Fiscal year 2021: -$35.53 million | Fiscal year 2020: -$12.78 million | Fiscal year 2019: -$19.38 million | Fiscal year 2018: -$16.87 million | Fiscal year 2017: -$14.32 million | Fiscal year 2016: -$18.62 million | Fiscal year 2015: -$15.56 million | Fiscal year 2014: -$15.15 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: